The high cost of capital for firms conducting medical research and development (R&D) has been partly attributed to the government risk facing investors in medical innovation. This risk slows down medical innovation because investors must be compensated for it. We propose new and simple financial...

'I have always thought authoritative lists such as "100 books you should read" are fascinating. So it is great to also have such a list available in one's professional field. Professor Diebold's book does just that; it compiles his list of academic research articles one should know in risk...